Fucoxanthin, a Marine Xanthophyll Isolated From Conticribra weissflogii ND-8: Preventive Anti-Inflammatory Effect in a Mouse Model of Sepsis
Background: Fucoxanthin (FX), a xanthophyll pigment which occurs in marine brown algae with remarkable biological properties, has been proven to be safe for consumption by animals. Although FX has various pharmacological effects including anti-inflammatory, anti-tumor, anti-obesity, antioxidant, ant...
Gorde:
Egile Nagusiak: | , , , , , , , , , , , , , |
---|---|
Formatua: | Liburua |
Argitaratua: |
Frontiers Media S.A.,
2019-08-01T00:00:00Z.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_9188554f1e7d493eb185b2a4d6fd1c85 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Jingqian Su |e author |
700 | 1 | 0 | |a Kai Guo |e author |
700 | 1 | 0 | |a Min Huang |e author |
700 | 1 | 0 | |a Yixuan Liu |e author |
700 | 1 | 0 | |a Jie Zhang |e author |
700 | 1 | 0 | |a Lijun Sun |e author |
700 | 1 | 0 | |a Lijun Sun |e author |
700 | 1 | 0 | |a Daliang Li |e author |
700 | 1 | 0 | |a Ka-Lai Pang |e author |
700 | 1 | 0 | |a Guangce Wang |e author |
700 | 1 | 0 | |a Guangce Wang |e author |
700 | 1 | 0 | |a Long Chen |e author |
700 | 1 | 0 | |a Zhiyu Liu |e author |
700 | 1 | 0 | |a Youqiang Chen |e author |
700 | 1 | 0 | |a Qi Chen |e author |
700 | 1 | 0 | |a Luqiang Huang |e author |
245 | 0 | 0 | |a Fucoxanthin, a Marine Xanthophyll Isolated From Conticribra weissflogii ND-8: Preventive Anti-Inflammatory Effect in a Mouse Model of Sepsis |
260 | |b Frontiers Media S.A., |c 2019-08-01T00:00:00Z. | ||
500 | |a 1663-9812 | ||
500 | |a 10.3389/fphar.2019.00906 | ||
520 | |a Background: Fucoxanthin (FX), a xanthophyll pigment which occurs in marine brown algae with remarkable biological properties, has been proven to be safe for consumption by animals. Although FX has various pharmacological effects including anti-inflammatory, anti-tumor, anti-obesity, antioxidant, anti-diabetic, anti-malarial, and anti-lipid, in vivo protective effect against sepsis has not been reported. In this study, we aimed at evaluation the efficacy of the FX in a model of sepsis mouse.Methods: FX was successfully isolated from Conticribra weissflogii ND-8 for the first time. The FX was identified by thin-layer chromatography (TLC), high-performance liquid chromatography-mass spectrometry (HPLC-MS), and nuclear magnetic resonance (NMR). Animals were randomly divided into 9 groups, including Sham group (mouse received an intraperitoneal injection of normal saline 1.0 ml/kg), FX-treated (0.1-1.0 ml/kg), Lipopolysaccharide (LPS)-treated (20 mg/kg), FX+LPS-treated (0.1-10.0 mg/kg and 20 mg/kg, respectively), and urinastatin groups (104 U/kg). Nuclear factor (NF)-κB activation could be potential treatment for sepsis. NF-κB signaling components were determined by western-blotting. IL-6, IL-1β, TNF-α production, and NF-κB activation were evaluated by ELISA and immunofluorescent staining in vitro.Results: FX was found to decrease the expression of inflammatory cytokines including IL-6, IL-1β, and TNF-α, in a prophylactic manner in the LPS-induced sepsis mouse model. Meanwhile, FX significantly inhibits phosphorylation of the NF-κB signaling pathway induced by LPS at the cellular level and reduces the nuclear translocation of NF-κB. The IC50 for suppressing the expression of NF-κB was 11.08 ± 0.78 μM in the THP1-Lucia™ NF-κB cells. Furthermore, FX also inhibits the expression of inflammatory factors in a dose-dependent manner with the IC50 inhibition of IL-6 production was 2.19 ± 0.70 μM in Raw267.4 macrophage cells. It is likely that the molecules with the ability of targeting NF-κB activation and inflammasome assembly, such as fucoxanthin, are interesting subjects to be used for treating sepsis. | ||
546 | |a EN | ||
690 | |a fucoxanthin,lipopolysaccharide | ||
690 | |a nuclear factor-κB | ||
690 | |a sepsis | ||
690 | |a Conticribra weissflogii | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Pharmacology, Vol 10 (2019) | |
787 | 0 | |n https://www.frontiersin.org/article/10.3389/fphar.2019.00906/full | |
787 | 0 | |n https://doaj.org/toc/1663-9812 | |
856 | 4 | 1 | |u https://doaj.org/article/9188554f1e7d493eb185b2a4d6fd1c85 |z Connect to this object online. |